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Abstract: 
Background 
Chromosome 22q11.2 deletion syndrome (22q11DS), the most common microdeletion in 
humans, is associated with multiple medical features, almost universal cognitive deficits, and a 
high risk of schizophrenia. The metabolic basis of the psychological/psychiatric features is not 
well understood. Volumetric brain imaging studies have shown that gray matter abnormalities in 
the dorsolateral prefrontal cortex (DLPFC), an area that is believed to be integral for higher 
neurocognition, as well as being involved in schizophrenia, are associated with the psychological 
manifestations. However, studies have not characterized any possible metabolite alterations 
within the DLPFC of children with 22q11DS and their correlations with the psychological 
findings. 
Methods 
We conducted a short echo time, single-voxel, in vivo proton spectroscopy study involving 
children with 22q11DS (n = 26) and matched control subjects (n = 23). 
Results 
Absolute N-acetylaspartate (NAA) levels from the DLPFC were significantly elevated in 
children with 22q11DS compared with control subjects and the elevations were associated with 
poor global functioning and higher rates of comorbid attention-deficit/hyperactivity disorder. 
Children with 22q11DS had a lack of an age-associated decrease in NAA levels, a trend seen in 
the control subjects. However, the results did not remain statistically significant after corrections 
for multiple comparisons were made. 
Conclusions 
These findings represent the first report of proton spectroscopy in children with 22q11DS. The 
elevated DLPFC NAA levels and the lack of decreasing trends in NAA with age in the 22q11DS 
group relative to control subjects suggest an alteration in cortical development. Also, such 
neuronal dysmaturation is associated with psychopathology in children with 22q11DS. 
ADHD | chromosome 22q11.2 deletion syndrome | DiGeorge syndrome | 1H MRS | Keywords: 
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Article: 
Chromosome 22q11.2 deletion syndrome (22q11DS), also known as DiGeorge syndrome or 
velocardiofacial syndrome, is the most common chromosomal microdeletion syndrome in 
humans, occurring in approximately 1 in 1600 live births ( [1] and [2]). It is associated with 
numerous and variable clinical manifestations, the more common of which are conotruncal heart 
abnormalities, palatal anomalies, hypoparathyroidism, and immune deficiency. Cognitive 
problems are seen in 80% to 100% of affected individuals and are highly variable, with deficits 
in visual-spatial processing, executive function, attention, verbal learning, working memory, 
arithmetic performance, language, and impaired functionality ( [3],[4] and [5]). Behavioral and 
emotional problems occur in about 50% of children with 22q11DS; the most common are 
attention-deficit/hyperactivity disorder (ADHD), social impairments, somatic complaints, and 
anxiety problems ( [5], [6], [7] and [8]). 22q11DS is also the most common identifiable genetic 
risk factor for schizophrenia; at least 25% of individuals with this deletion develop a 
schizophrenia-like psychosis by young adulthood (9). The exact pathophysiology of the 
cognitive/behavioral/emotional/psychiatric manifestations of the condition remains unexplained, 
although undoubtedly the hemizygous deletion of several genes predisposes to these deficits. 
In attempts to quantify the structural correlates of the neurocognitive manifestations, brain 
imaging studies have delineated several areas of gray matter (GM) volumetric reductions in 
individuals with 22q11DS, mainly in the posterior cortical regions and the cerebellum (10). An 
area of special interest is the left dorsolateral prefrontal cortex (DLPFC), which, together with its 
other cortical and subcortical circuits, plays an important role in attention, working memory, 
planning, reasoning, and execution (deficits that are integral to the neurocognitive phenotype in 
22q11DS) ( [11] and [12]). 
Voxel-based morphometric studies have shown volumetric reduction in the DLPFC gray matter 
volume in individuals with 22q11DS ( [13] and [14]); this reduction is associated with deficits in 
sustained attention and executive function (14) and may be predictive of risk for schizophrenia-
like psychotic symptoms in these patients in later life. Nonetheless, it is also evident that relative 
to other brain regions, the frontal lobes show less volumetric reduction in children with 22q11DS 
( [14] and [15]). This may suggest an alteration in the normal pruning of overproduced synaptic 
connections, which in the DLPFC occurs in adolescence ( [16],[17], [18], [19] and [20]). Thus, it 
is possible that pruning may occur later in children with 22q11DS than in typically developing 
children (10) and the delayed change in morphology of the frontal lobes may be associated with 
some of the neurocognitive abnormalities in the condition (14). 
Further investigation using noninvasive neurochemical imaging techniques, such as in vivo 
proton magnetic resonance spectroscopy (1H MRS), could yield important information about the 
brain developmental alterations, but such studies are lacking in children with 22q11DS. Proton 
magnetic resonance spectroscopy allows for the in vivo analysis of neurometabolite levels, such 
as N-acetylaspartate (NAA), a neurometabolite present almost exclusively in the nervous system 
( [21] and [22]) and sensitive to brain development. In cortical areas, NAA increases with age, 
with changes most prominent in early postnatal development ([23] and [24]), followed by 
decreases in prefrontal NAA levels in adolescence and early adulthood ( [25],[26] and [27]). 
Collectively, the increase followed by decreasing NAA levels with age in the prefrontal cortex 
may reflect the overproduction of dendrites and synaptic terminals, followed by the normal 
pruning of synapses that occur during cortical brain maturation ( [20], [26], [28] and [29]), 
although conclusive evidence is lacking. In contrast, NAA levels have been reported as being 
relatively stable or increasing linearly with age in white matter (WM) tissue during brain 
development ( [26] and [30]). Therefore, NAA is believed to be a marker of functioning neurons 
or, more specifically in the context of development, a marker of cortical maturation (29). NAA 
has been measured in several neurologic and psychiatric disorders, with the aim of understanding 
the pathophysiology of the particular disorder, including ADHD, wherein considerable 
variability in neurometabolites has been reported (31). To our knowledge, there have been no 
studies, so far, that have reported neurometabolite findings in DLPFC in children with 22q11DS. 
One recent study of 1H MRS in adults with 22q11DS found no differences in DLPFC 
metabolites between individuals with and without schizophrenia (32). 
Proton magnetic resonance spectroscopy studies in individuals with schizophrenia in the general 
population have consistently reported decreased NAA within several brain regions, including the 
left DLPFC (both gray and white matter), in individuals with chronic schizophrenia and not in 
most first-episode studies ([33] and [34]). Decreased NAA in the DLPFC may suggest a 
reduction in functioning neurons in the cortex (27). A few 1H MRS studies in individuals at high 
risk for schizophrenia (other than 22q11DS) have shown varying reductions of NAA in 
prefrontal areas ( [27] and [35]) and one reported increased NAA in prefrontal white matter in 
these individuals (36), but a recent meta-analysis reported that there were no NAA abnormalities 
in the frontal areas in individuals at high risk (offspring of individuals with schizophrenia) in the 
general population (33). Thus, there are no specific trends in the neurometabolites in these 
individuals at high risk for schizophrenia. 
The aim of the current study was to investigate possible neurometabolite alterations in the 
DLPFC of nonpsychotic children with 22q11DS compared with healthy control subjects and to 
determine the neuropsychological correlates of these neurometabolites before the onset of 
psychosis. Additionally, due to significant changes in proton (1H) metabolite levels with age in 
typically developing individuals, possible age effects are also investigated. Based on our 
previous findings of a correlation between DLPFC gray matter volumetric reduction and 
neurocognition (14), as well as strong empirical evidence that the left DLPFC is involved in 
schizophrenia and is abnormal in individuals at high risk for the disorder 
( [27], [34], [37] and [38]), we hypothesized that our cohort of children with 22q11DS (at high 
risk of psychosis) would show reduced NAA in the left DLPFC and that the reduced NAA would 
be correlated with neuropsychological functioning. 
Methods and Materials 
This cross-sectional study was approved by the Institutional Review Board of Wake Forest 
University Health Sciences. Participants included 26 patients with 22q11DS and 23 healthy 
control subjects. The 22q11DS subjects were enrolled in the study through the Genetics Clinic at 
Wake Forest University and the control subjects were recruited through the local pediatric 
practices and public school systems. The 22q11DS and control subjects were matched for age 
and gender. They were not matched for handedness, but there were no significant differences in 
handedness between the two groups (χ2 = .002, p = .96). Exclusion criteria for both groups were 
a psychotic disorder and age above 16 years; for the control subjects, exclusion criteria included 
the presence of a neurodevelopmental or genetic disorder. All children with 22q11DS had a 
molecularly confirmed deletion of the 22q11.2 interval, with either fluorescence in situ 
hybridization (Vysis, Gaithersburg, Maryland) or microarray analyses (Affymetrix, Santa Clara, 
California; www.affymetrix.com). 
Neuropsychological Measures 
The participants underwent a battery of neuropsychological tests; parental interviews were also 
conducted. These included the Wechsler Intelligence Scale for Children-Fourth Edition (39) 
(earlier participants were administered the Wechsler Intelligence Scale for Children-Third 
Edition [40]); Wechsler Individual Achievement Test-Second Edition (41); Wisconsin Cart 
Sorting Test (42); Continuous Performance Test, identical pairs and AX conditions (task in 
which the user presses the button when the letter X is preceded by the letter A) (43); and the 
Computerized Diagnostic Interview Schedule for Children (44). Global assessment of 
functioning by an examiner-rated scale (Global Assessment of Functioning [GAF]) was also 
ascertained for all participants, providing ratings of overall function, independent of specific 
mental health diagnoses (45). 
Single-Voxel 1H Spectroscopy 
Magnetic resonance images were conducted with a 1.5 T GE Signa imaging system (GE Medical 
Systems, Milwaukee, Wisconsin). A set of sagittal and axial scout images were first obtained to 
ascertain subject position and quality of images. A three-dimensional spoiled gradient recalled 
acquisition (repetition time [TR] = 25 msec, echo time [TE] =5 msec, flip angle = 400, field of 
view = 240 × 180 mm, slice thickness = 1.5 mm, matrix = 256 × 192) was performed in the 
coronal plane to obtain 124 images covering the entire brain for tissue segmentation. A fast spin 
echo sequence (two-dimensional fast spin echo; TR = 2500 msec; TE2 = 17/102 msec; echo train 
length = 8; field of view = 240 mm2, with 24 slices; slice thickness = 5 mm; gap = 0 mm; 
number of excitations = 1; matrix = 256 × 192) was also obtained for T2 and proton density 
images in the coronal plane. Based on the scout images, a 2.0 × 2.0 × 2.0 cm2 voxel was placed 
in the left DLPFC to acquire the in vivo singe-voxel, short echo time 1H spectroscopy using the 
point-resolved spectroscopy sequence and the following parameters: TE = 35 msec, TR = 1500 
msec, bandwidth = 2 kHz, 2048 complex data points, and 128 acquisitions. The superior frontal 
sulcus, the lateral fissure, and the genu of the corpus callosum were used as anatomical 
boundaries for the voxel placement in the DLPFC (Figure 1). Water-unsuppressed spectra were 
also acquired for spectral line shape correction (46) and for absolute quantification of 1H 
metabolite levels with millimoles per kilogram wet weight units. The 1H metabolites, glutamate, 
glutamine, myo-inositol, choline-containing compounds (glycerophosphocholine [GPC] + 
phosphocholine [PC]), phosphocreatine plus creatine (PCr + Cr), NAA, and N-
acetylaspartylglutamate, as well as taurine, alanine, aspartate, gamma-aminobutyric acid, 
glucose, and lipid resonances and macromolecule resonances (47) were quantified using the 
Linear Combination Model software (LCMODEL Inc., Ontario, Canada) (48), an operator-
independent fitting routine. The 1H metabolites with reasonable level of fitting confidence (i.e., 
the metabolites with an overall mean Cramer-Rao lower bound value of less than 20%) were the 
dependent variables in this analysis and included NAA, PCr + Cr, GPC + PC, myo-inositol, and 
glutamate. To address the variability in the tissue composition within the voxels of interest, the 
proportions of GM, WM, and cerebrospinal fluid (CSF) were estimated for each localized 1H 
spectroscopy voxel. In a fully automated procedure, the T1-weighted images were corrected for 
any B1 field bias followed by extracting the brain tissue and segmenting the images into partial 
volume maps of GM, WM, and CSF space using FSL (FMRIB Analysis Group, Oxford, United 
Kingdom) tools (49). The tissue fractions within the voxels of interest were then extracted from 
the segmented images by matching the coordinates of the 1H spectroscopy voxel with the images 
using the FSL tools. The GM, WM, and CSF voxel content values, along with the other 
appropriate relaxation correction factors (23), were then utilized to obtain absolute quantification 
values, as described elsewhere (50). 
 
 
 
Figure 1. A typical proton magnetic resonance spectroscopy spectrum is illustrated along 
with voxel placement in the subjects. Cr, creatine; GPC, glycerophosphocholine; myo-
Ins, myo-inositol; NAA, N-acetylaspartate; PC, phosphocholine; PCr, phosphocreatine. 
 
Statistical Methods 
Statistical tests were performed with SPSS version 18.0 (IBM Corporation, Armonk, New York), 
with independent sample t tests or univariate analysis of variance for continuous variables and 
Fisher's exact test for categorical variables to examine the differences in neuropsychological 
functioning between the two groups. The group differences in NAA, PCr + Cr, GPC + PC, 
glutamate, and myo-inositol levels were examined with independent sample t tests. Medication 
status, age, and gender were used as covariates in univariate analyses of variance to determine if 
the results of the group differences were influenced by these factors. Pearson correlations were 
computed to determine associations between the neurometabolites and psychological 
functioning. Although our analyses were based on an a priori hypothesis, we present data before 
and after statistical corrections for multiple comparisons, although some studies involving 
22q11DS do not adopt such corrections (32). To assess age effects, a group-by-age interaction 
model was also included. 
Results 
Demographics 
There were no significant differences in age, gender, ethnicity, or parental socioeconomic status 
between the 22q11DS and control groups. The patient and control groups did not differ on sex 
composition (65% male and 54% male subjects, respectively), ethnic composition (92% 
Caucasian and 8% African American and 84% Caucasian, 8% African American, and 8% 
Hispanic, respectively), age (10.9 ± 2.6 years and 11.0 ± 2.2 years, respectively), handedness 
(χ2 = .004, p = .99), or socioeconomic status (SES) (SES in 22q11DS group = 32.8 [13.1] and 
SES in control group = 30.5 [12.3]). Medications in the 22q11DS and control groups consisted 
of stimulants for ADHD and anxiolytics, with 8 of 26 children with 22q11DS and 7 of 23 control 
children on a medication, with no significant group differences (Fisher's exact test p = 1.0). 
Neuropsychological Measures 
The 22q11DS group exhibited poorer neuropsychological performance than the control group, 
with significant differences in verbal comprehension, perceptual organization, working memory, 
processing speed, achievement, sustained attention, executive function, and verbal learning 
(Table 1) (some data previously published) (4). There was no difference in the incidence of 
anxiety and ADHD between the two groups. None of the subjects had a psychotic illness at the 
time of the study. 
 
Table 1. Abnormalities in Neuropsychological Functioning in Children with 22q11DS 
Compared with Matched Control Subject 
Test Group Number Mean (SD) t Statistic 
GAF 22q11DS 26 66.3 (8.8) −2.07a 
Control 23 71.7 (9.3) 
WISC Verbal 
Comprehension 
22q11DS 25 75.0 (8.8) −8.35b 
Control 23 103.1 (14.0) 
WISC Perceptual 
Organization 
22q11DS 25 77.0 (10.1) −7.6b 
Control 23 104.3 (14.2) 
WISC Working Memory 22q11DS 25 83.2 (12.2) −5.53c 
Control 23 103.3 (12.8) 
WISC Processing Speed 22q11DS 25 78.2 (12.7) −5.9b 
Control 23 99.2 (11.8) 
WIAT Broad Reading 22q11DS 25 81.3 (14.1) −4.8b 
Control 23 101.2 (15.1) 
WIAT Broad 
Mathematics 
22q11DS 18 76.1 (18.3) −5.23b 
Control 22 103.09 (14.21) 
WCST Perseverative 
Errors 
22q11DS 26 89.8 (11.7) −3.14c 
Control 23 102.61 (14.7) 
CPT AX Sustained 
Attention 
22q11DS 25 1.54 (1.17) −3.37c 
Control 23 2.73 (1.21) 
Test Group Number Mean (SD) t Statistic 
CPT IP Sustained 
Attention 
22q11DS 25 .46 (.53) −4.19c 
Control 23 1.25 (.76) 
DISC Anxiety Disorders 22q11DS 26 10/26 Fisher's exact 
test p < .01 Control 23 1/23 
DISC ADHD 22q11DS 26 8/26 Fisher's exact test ns 
Control 23 6/23 
22q11DS, chromosome 22q11.2 deletion syndrome; ADHD, attention-
deficit/hyperactivity disorder; AX, ; CPT, Continuous Performance Test; DISC, 
Diagnostic Interview Schedule for Children; GAF, Global Assessment of Functioning; 
IP, identical pairs; ns, nonsignificant; WCST, Wisconsin Cart Sorting Test; WIAT, 
Wechsler Individual Achievement Test; WISC, Wechsler Intelligence Scale for Children. 
a 
p < .05. 
b 
p < .001. 
c 
p < .01. 
 
Neurometabolites and Overall Quality of the 1H MRS 
Figure 1 includes the spectral modeling using Linear Combination Model of a typical in vivo 1H 
spectrum from the left DLPFC. The mean full width at half maximum of the NAA for 22q11DS 
and control subjects were 2.7 ± .7 Hz and 2.5 ± .6 Hz and the mean signal-to-noise ratios were 
10.0 ± 1.6 and 9.9 ± 1.8, respectively; both were nonsignificant. The mean Cramer-Rao lower 
bound values of NAA, NAA + N-acetylaspartylglutamate, glutamate, glutamate + glycine, myo-
inositol, PCr + Cr, and GPC + PC are noted in Table 2. Additionally, there were no significant 
differences in gray matter fraction within the 1H spectroscopy voxel between the 22q11DS and 
control groups, as presented in Table 2. NAA levels were significantly higher in the 22q11DS 
group relative to the control group and this group difference in NAA remained significant when 
ADHD medication status was used as a covariate (univariate analysis of variance, F = 4.5, p < 
.05), as well as using age, gender as covariates (univariate analysis of variance, F = 4.1, p < .05). 
Other neurometabolites did not significantly differ between the two groups. 
 
Table 2. Comparison of 1H Metabolite Levels Within the Left DLPFC in Children with 
22q11DS and Control Subjects 
1H 
Metabolites 
Group Total 
Number 
Mean Level ± 1 SD 
(CV%) mmol/kg w.w. 
tStatistic CRLB ± 1 
SD 
NAA 22q11DS 26 11.3 ± .9 (8.1) 2.14a 7.0 ± 1.1 
Control 23 10.7 ± .9 (8.7) 7.2 ± 1.3 
NAA + 22q11DS 26 11.7 ± .95 (8.2) 2.68a 6.0 ± .52 
1H 
Metabolites 
Group Total 
Number 
Mean Level ± 1 SD 
(CV%) mmol/kg w.w. 
tStatistic CRLB ± 1 
SD 
NAAG Control 21 10.9 ± .96 (8.8) 6.4 ± .74 
Glu + Gln 22q11DS 26 10.2 ± 1.3 (12.8) −.13 9.8 ± 1.5 
Control 23 10.2 ± 1.24 (12.2) 9.74 ± 1.7 
Myo-inositol 22q11DS 26 3.4 ± .6 (17) −.94 12.9 ± 2.8 
Control 23 3.6 ± .5 (14) 12.2 ± 1.9 
PCr + Cr 22q111DS 26 6.7 ± .7 (11) 1.28 8.3 ± .8 
Control 23 6.5 ± .7 (11) 8.6 ± 1.1 
GPC + PC 22q11DS 26 1.4 ± .2 (17) −.51 9.0 ± 1.4 
Control 23 1.5 ± .2 (16) 9.0 ± 1.4 
Gray Matter 
Voxel 
Fraction 
22q11DS 26 45.9 ± 10.4 .04  
Control 23 46.1 ± 9.9 
When corrections for multiple comparisons are made, the group differences in NAA are 
no longer significant.22q11DS, chromosome 22q11.2 deletion syndrome; Cr, creatine; 
CRLB, Cramer-Rao lower-bound value; CV, coefficient of variation in percentages; 
DLPFC, dorsolateral prefrontal cortex; Gln, glutamine; Glu, glutamate; GPC, 
glycerophosphocholine; 1H, proton; NAA, N-acetylaspartate; NAAG, N-
acetylaspartylglutamate; PC, phosphocholine; PCr, phosphocreatine; SD, standard 
deviation; w.w., wet weight. 
a 
p < .05. 
Age Effects 
There were no significant correlations with age for the metabolites, except for myo-inositol, 
which was negatively correlated with age in the 22q11DS group (Pearson r = −.47, p < .05) but 
not in the control group (Pearson r = .20, p = .35). The control group showed a trend toward 
decreasing NAA levels with age, although not significant (Pearson r = −.32, medium effect size), 
which was absent in the 22q11DS group (r = −.030). The relationship between age and NAA 
levels in the two groups is illustrated in Figure 2. 
 
Figure 2. The linear relation of N-acetylaspartate (NAA) and age did not differ 
significantly between the two groups, although there was a trend toward lower levels with 
age in the control group (r = −.32) not seen in the chromosome 22q11.2 deletion 
syndrome (22q11DS) group (r = −.030). w.w., wet weight. 
 
We divided the 22q11DS children and the control subjects in two groups based on the median 
age in each group (10.6 years in the 22q11DS group and 11.1 years in the control group). A 
significantly higher mean NAA level was seen in younger control subjects, compared with the 
older ones (11.16 [.96] and 10.22 [.65], respectively, t statistic = 2.60, p < .05). There was no 
significant difference in the mean NAA levels in children with 22q11DS who were above and 
below the median age 11.29 (.93) and 11.31 (.93), respectively. There was also a significantly 
higher mean NAA level in older children with 22q11DS relative to older control subjects (11.29 
[.93] and 10.27 [.64], respectively, F = 9.3, p < .01). In contrast, the NAA levels were not 
significantly different between the younger 22q11DS and control children (11.31 [.93] and 10.27 
[.64], respectively). These results confirm the divergence in NAA levels with increasing age, as 
illustrated in Figure 2. 
When Bonferroni corrections were applied due to the multiple comparisons that were used, the 
differences in the groups and age on NAA and myo-inositol levels were no longer significant. 
Relationship between Neuropsychological Functioning and NAA Levels 
We then examined the relationship between NAA levels and neuropsychological functioning, 
since NAA differed between the two groups. A significant relationship was found between NAA 
and global functioning (GAF) in the 22q11DS group (Table 3 and Figure 3). The interaction term 
of group by NAA was not significant for GAF scores. The mean NAA level was significantly 
higher in children with 22q11DS who had ADHD compared with those that did not have this 
diagnosis (Table 3). No such relationships between ADHD diagnosis, GAF, or other 
neuropsychological measures and NAA levels were evident in the control group. To account for 
the effects of ADHD medication on the correlation between NAA and global functioning, we 
performed Pearson partial correlations with ADHD medications as a covariate and found that the 
correlations between NAA levels and GAF (r = −.43, p < .05) remained significant. We did not 
find a significant correlation between full-scale IQ, verbal comprehension, or perceptual 
organization indices and NAA levels in either the 22q11DS or control groups. 
 
Table 3. Relationship of NAA Levels and Neuropsychological Findings in Children with 
22q11DS 
Dependent Measure Pearson 
Correlation/t Test 
GAF −.437ab 
DISC Inattention Symptoms .156 
DISC Hyperactive Symptoms .16 
DISC Any Diagnosis .035 
WISC Verbal Comprehension Factor .116 
WISC Working Memory −.314 
WISC Perceptual Organization Factor −.019 
WISC Processing Speed Factor −.222 
WIAT Broad Reading −.151 
WIAT Broad Mathematics −.383 
WCST Perseverative Errors −.076 
CPT AX Sustained Attention −.072 
CPT IP Sustained Attention .128 
DISC ADHD (NAA Levels of Subjects with and without 
ADHD) 
t statistic = −2.50ab 
DISC Any Anxiety Disorder (NAA Levels of Subjects with and 
without Anxiety Disorder) 
t statistic = .488 
Effect size: .1 = small, .3 = moderate, and ≥.5 = large.22q11DS, chromosome 22q11.2 
deletion syndrome; ADHD, attention-deficit/hyperactivity disorder; AX, task in which 
the user presses the button when the letter X is preceded by the letter A; CPT, Continuous 
Performance Test; DISC, Diagnostic Interview Schedule for Children; GAF, Global 
Assessment of Functioning; IP, identical pairs; NAA, N-acetylaspartate; ns, 
nonsignificant; WCST, Wisconsin Cart Sorting Test; WIAT, Wechsler Individual 
Achievement Test; WISC, Wechsler Intelligence Scale for Children. 
a 
p < .05. 
b 
Moderate and large effect sizes. 
 
Figure 3. Scatter plots demonstrating the correlation between Global Assessment of 
Functioning (GAF) andN-acetylaspartate (NAA) in children with chromosome 22q11.2 
deletion syndrome (22q11DS) and control subjects: NAA has a strong correlation with 
GAF in the 22q11DS group and this is not present in the control subjects (group 1 = 
22q11DS; group 2 = control subjects). w.w., wet weight. 
Discussion 
To our knowledge, this is the first study of 1H spectroscopy findings in children with 22q11DS. 
In contradiction to our hypothesis, mean absolute NAA level in the left DLPFC in our cohort of 
22q11DS patients was higher than in the control group, with decreasing NAA levels with age in 
the control group but not in the 22q11DS group. Although the results were not significant once 
corrections for multiple comparisons were applied, the evidence is suggestive that the 
developmental trajectory of NAA levels may be different in the two groups. 
NAA, which is the second most abundant free amino acid in the brain next to glutamate, is 
synthesized in neuronal mitochondria from acetyl coenzyme A (acetyl-CoA) and aspartate by the 
membrane-bound enzyme L-aspartate N-acetyltransferase, and the principal metabolizing 
enzyme, N-acetyl-L-aspartate aminohydrolase II (aspartoacylase), is primarily localized in white 
matter with highest activity in oligodendrocytes (51). This is consistent with cell culture studies 
showing that NAA is localized in both neurons, oligodendrocytes, and in oligodendrocyte-type-2 
astrocyte progenitor cells ( [52] and [53]) and provides evidence of intercompartmental cycling 
of NAA between neurons and oligodendrocytes ( [51],[52] and [54]). Thus, NAA may be a 
marker of functioning neuroaxonal tissue that includes functional aspects of the formation and/or 
maintenance of myelin (54). However, in the context of brain development, NAA levels do show 
dynamic age-related changes. Early in postnatal brain development, cortical NAA levels are low; 
NAA dramatically increases in early postnatal development ( [23] and [24]) and reaches a 
plateau in later childhood/early adolescence followed by decreasing levels in late adolescence 
and early adulthood (i.e., similar to an inverted-U trajectory) ( [25], [26], [27] and [30]). 
Specifically, the brain regions showing greatest NAA elevations during development include the 
cortical gray matter, cerebellum, and the thalamus (30). This provides additional evidence that 
NAA does not merely reflect the number of neurons but is a marker of functioning neurons. 
Additionally, in the context of development, the timing of the inverted-U trajectory of NAA is 
consistent with the temporal maturation of the prefrontal cortex ( [29], [30] and [55]). Therefore, 
the nonprogressive decreasing NAA levels in 22q11DS compared with control subjects suggest a 
developmental deviation in 22q11DS. The decreasing myo-inositol with age in 22q11DS 
contrasted by age-invariant changes in control subjects suggests there is decreasing glial content 
in 22q11DS, which may or may not be related to the lack of synaptic pruning. Interestingly, low 
levels of myo-inositol have been reported in individuals with long-standing schizophrenia, 
thought to be related to reduced glial activity (56). Further investigation is warranted. 
Our finding of higher NAA levels within the DLPFC could be a sensitive indicator of 
neuropathology in 22q11DS, since NAA is an indicator of neuronal integrity, whereas 
volumetric studies are an indirect indicator of underlying neuronal pathology, with gray matter 
consisting of a complex combination of neurons with dendrites and synapses, as well as glia and 
vasculature (17). Further evidence for altered neuronal development in 22q11DS is provided by 
altered cortical development in children with the condition ([57] and [58]). Although the exact 
cause of the higher NAA in our cohort of children with 22q11DS is unclear, several mechanisms 
could exist. One possibility is that there is an increase in gray matter neuronal volume within the 
voxel that we placed in the DLPFC. However, although frontal lobe gray matter volumes are 
relatively preserved in children with 22q11DS ( [14], [15] and [59]), an actual increase in gray 
matter in this area has not been reported. An alternate explanation is that the volumetric gray 
matter reductions within the DLPFC, which we reported previously in children with 22q11DS, 
could involve only nonneuronal tissue, with preservation of neuronal tissue or even an excess of 
it, effectively altering the ratio of neuronal to nonneuronal tissue. 
We performed voxel segmentation analyses and there were no group differences in the gray 
matter tissue percentages, and tissue fraction values were then used in the calculation of absolute 
metabolite concentration levels. Thus, our results reflect gray matter neurometabolite levels and 
thus would not be reflective of white matter, although white matter volumetric abnormalities are 
common in 22q11DS ([60] and [61]). We did not correlate gray matter volumes in the DLPFC 
with the NAA levels, since the voxel we placed would not capture all of the DLPFC, and 
additionally, the gray matter composition of the voxel was approximately 50% and thus valid 
inferences could not be made about the volume of the DLPFC and the NAA levels. The only 
other study of brain 1H MRS in individuals with 22q11DS was in a small group of adults, 
comparing those with schizophrenia with those without schizophrenia and control subjects. 
There were no significant changes in neurometabolites in the DLPFC between the groups, but 
interestingly, the authors noticed a trend toward higher levels of neurometabolites in the 
22q11DS group without schizophrenia compared with the healthy control subjects and 22q11DS 
individuals with schizophrenia (32). It was postulated that neurometabolites may be higher in 
individuals with 22q11DS before psychosis and that in the transition toward psychosis the levels 
of neurometabolites would decrease. Ongoing longitudinal studies on our cohort would enable 
further examination of this hypothesis. 
Our finding of an increased DLFPC NAA in 22q11DS being related to ADHD and decreased 
GAF is intriguing. A relative increase in neuronal versus nonneuronal tissue due to neuronal 
dysmaturation in children with 22q11DS could be associated with elevated NAA and lower 
global functioning and higher rates of ADHD. Studies on ADHD in the general population show 
reduced NAA in prefrontal cortex and an elevated NAA/PCr + Cr ratio 
( [31], [62], [63] and [64]), but the reports are inconsistent, with some studies reporting no 
abnormalities in prefrontal cortex NAA in association with ADHD (31). The elevation of NAA 
that we found is more likely to be due to neuronal dysmaturation than a compensatory 
mechanism to lower neurocognition in children with 22q11DS, since the elevated NAA is 
associated with lower functionality and ADHD and not with IQ. Delayed cortical maturation is 
thought to be related to the impulsivity and inattention seen in ADHD in the general population 
( [65] and [66]). Our preliminary report needs to be confirmed in larger cohorts, as well as in a 
longitudinal manner. 
In comparing the findings of our study with those seen in spectroscopy studies of individuals 
with schizophrenia and those at high risk for the disorder in the general population, we did not 
see a reduction in NAA within the DLFPC in children with 22q11DS, who are considered to be 
at high risk for schizophrenia in later life. Although this was contrary to our expectation, the 
elevated NAA in our study may be related to abnormalities in brain maturation in 22q11DS. 
Further longitudinal studies in children with 22q11DS and high-risk individuals in the general 
population are needed for clarity on the relationship between neurometabolites in the DLPFC 
and the psychosis risk. 
The advantages of our study were that we only had children who were nonpsychotic and thus the 
effects of psychosis on psychological function and NAA levels were not confounds; our subjects 
were not recruited from one referral source, such as the pediatric cardiology or child psychiatry 
clinic, and thus are representative of the wide spectrum of manifestations seen in 22q11DS. 
In conclusion, children with 22q11DS demonstrate elevated levels of NAA in conjunction with 
higher rates of ADHD and lower global function. The increase in NAA in 22q11DS children 
may be reflective of relatively preserved neuronal tissue in the DLPFC due to delayed neuronal 
maturation and synaptic pruning. The relationship between ADHD and global functioning with 
the NAA levels underscores the importance of alterations of neurometabolites that are not 
directly related to the deleted genes, but rather a consequence of altered neuronal 
maturation/structure, in mediating the psychological abnormalities in these children. 
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